) has appointed Scott Jackson, former chief executive officer of Celator Pharmaceuticals, Inc., to its board of directors, the company said.
Total death (n = 915) Glyc
A 1.27 1.17 (1.19-1.35) (1.09-1.25) <0.0001 <0.0001 hsCRP 1.13 1.07 (1.07-1.2) (1-1.14) <0.0001 0.0398 IL-6 1.26 1.2 (1.2-1.32) (1.14-1.26) <0.0001 <0.0001 D-dimer 1.09 1.08 (1.06-1.13) (1.04-1.12) <0.0001 <0.0001 B.
Limited Tenders are invited for Supply of Pr Gauges : Glycerine filled pressure gauge-0- 40 kg/cm2,type: direct, mounting: lo cal, dial size: 150 mm.,case: ss 304, ring: standard, fill fluid: glyc
erine, lens: shatterproof glass, element: bourdon, bourdon mat.: aisi 316 ss, movement mat.: aisi 304 ss, accuracy:+/-1% or better, ext scre w mat.:ss, pointer type:micrometer, zero:adjust: yes, integral damping screw: yes, wetted parts: ss 304
* GlycoMimetics Inc (NASDAQ: GLYC
)(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
After surveying 25 sickle cell disease experts, Piper Jaffray analyst Danielle Brill is "incrementally more bullish" on both GlycoMimetics (GLYC
) and Global Blood Therapeutics (GBT) into their upcoming catalysts.
) has dosed first patient in the company's Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory AML, the company said.
Hubert Vesper: TG are determined by measuring glyc
erol after hydrolysis of TG.
* Piper Jaffray downgraded the previous rating for GlycoMimetics Inc (NASDAQ: GLYC
) from Overweight to Neutral.
After speaking to a practicing hematologist and emergency medicine doctor at a leading medical institution, Piper Jaffray analyst Danielle Brill is "incrementally more bullish" on both GlycoMimetics (GLYC
) and Global Blood Therapeutics (GBT).
) intends to offer and sell, subject to market conditions, 4.5m shares of its common stock in an underwritten public offering, the company said.
(16.) GISSI-3: Effects of lisinopril and transdermal glyc
eryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction.
GlycoMimetics, Inc.(NASDAQ: GLYC
) shares tumbled 61% to $3.59 after the company announced Pfizer's Phase 3 clinical trial evaluating Rivipansel in Sickle Cell did not meet its Primary or key Secondary endpoints.